Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

BACKGROUND: Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib. MATERIALS, AND METHODS: Hepatic adverse reactions (ARs) were assessed by type and magnitude o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Lewis, James H., Gelderblom, Hans, van de Sande, Michiel, Stacchiotti, Silvia, Healey, John H., Tap, William D., Wagner, Andrew J., Pousa, Antonio Lopez, Druta, Mihaela, Lin, Chia‐Chi, Baba, Hideo A., Choi, Youngsook, Wang, Qiang, Shuster, Dale E., Bauer, Sebastian
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2020
Soggetti:
Sarcomas
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100574/
https://ncbi.nlm.nih.gov/pubmed/33289960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13629
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi